<DOC>
	<DOCNO>NCT00002883</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It know whether combine chemotherapy surgery effective surgery alone . PURPOSE : Randomized phase III trial compare effectiveness surgery without combination chemotherapy treat patient cancer esophagus .</brief_summary>
	<brief_title>Surgery With Without Combination Chemotherapy Treating Patients With Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient operable adenocarcinoma low third esophagus cardia treat fluorouracil/cisplatin vs. chemotherapy prior surgical resection . - Assess whether neoadjuvant fluorouracil/cisplatin increase tumor resectability . OUTLINE : This study randomize neoadjuvant chemotherapy . Patients stratify performance status , tumor location , randomize center . Patients randomize neoadjuvant chemotherapy undergo resection tumor adequate margin resection regional lymph node ( R2 least 8 nodal group recommend ) . Patients randomize neoadjuvant chemotherapy receive fluorouracil cisplatin 3-4 week interval ; fluorouracil give continuous intravenous infusion 5 day cisplatin give first 2 day fluorouracil administration . Tumor response assess 2 course ; respond patient serious toxicity receive third course . Surgery , , initiate 4-6 week second third course chemotherapy . Upon recovery ( within 3-6 week ) , patient respond neoadjuvant chemotherapy receive 3-4 additional course postoperative chemotherapy ( maximum total 6 course ) . Patients whose best response stable disease assess postoperative radiotherapy . Patients either arm positive resection margin , positive lymph node , equivocal complete resection refer postoperative radiotherapy . Further therapy patient incomplete resection discretion physician . Patients follow every 3-4 month least 5 year . PROJECTED ACCRUAL : A total 250 patient enter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Adenocarcinoma low third esophagus cardia complete resection feasible Extension cardia allow Cancer cardia extension esophagus stomach allow No situ cancer cardia No distant metastases PATIENT CHARACTERISTICS : Age : Not 75 Performance status : WHO 0 1 Hematopoietic : WBC least 4,000 Polymorphonuclear lymphocyte great 2,000 Platelets least 100,000 Hepatic : Not specify Renal : Creatinine le 1.3 mg/dL ( 120 micromoles/L ) Cardiovascular : No prior myocardial infarction No cardiac contraindication surgery Pulmonary : No respiratory contraindication surgery Other : No second malignancy except : Basal cell carcinoma skin Adequately treat situ carcinoma uterine cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy tumor cardia Endocrine therapy No prior radiotherapy tumor cardia Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>